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Tumour-promoting phorbol esters (phorbol-lZmyristate-13-acetate, PMA; phorbol-12,13_dibutyrate, 
PDBu) but not 4#?-phorbol, activate protein kinase C. Using human platelets pre-labelled with quin2 or 
32P04 we examined the effects of these compounds on human platelet cytosolic free Caz+ ([Ca2+],) and on 
[32P]phosphatidic a id ([3zP]PtdOH). PMA and PDBu, but not 4p-phorbol inhibited thrombin-, PAF- and 
vasopressin-induced elevation of [Caz+li and [32P]PtdOH formation. It is suggested that protein kinase C 
may act to terminate the transduction processes that link receptor occupancy to cellular activation. 
Platelet Phorbol ester Protein kinase C Polyphosphoinositide Calcium 
1. INTRODUCTION 
In platelets, as in other cell types, agonist- 
receptor interaction at the plasma membrane 
modulates the levels of specific second messenger 
molecules that, in turn, influence the rates of those 
key biochemical reactions governing the cellular 
response. Inhibition of platelet responsiveness i  
associated with an elevation of the intracellular 
concentration of CAMP [ 11. In contrast, stimula- 
tion of platelet responsiveness i associated with an 
elevation of the intracellular concentrations of 
cytosolic free Ca’+ ([Ca2’]i) and 1,2-diacylglycerol 
(DAG) [2,3] as a consequence of a common 
receptor-operated transduction process: inositol 
phospholipid hydrolysis [4]. Agonist-induced 
hydrolysis of phosphatidylinositol (PtdIns), 
PtdInd-phosphate (PtdIns4P) or, more likely, 
PtdIns4,5_bisphosphate (PtdIns4,5P2) by phos- 
pholipase C yields DAG and the corresponding in- 
ositol phosphate(s). Inositol 1,4,5_trisphosphate 
(Ins(1,4,5)P3) can mobilise Ca2+ from intracellular 
(non-mitochondrial) stores [5], and phosphatidic 
acid (PtdOH) the immediate product of DAG 
metabolism, may exert Ca2+ ionophoric effects [6]. 
DAG, via activation of protein kinase C, and 
elevated [Ca2+]i, via activation of Ca2+-calmodulin 
dependent protein kinase(s), may act independent- 
ly or synergistically to induce platelet activation. 
The effects of endogenous DAG on protein kinase 
C and on cellular responsiveness can be mimicked 
by tumour promoting phorbol esters (e.g., phor- 
bol-12-myristate-13-acetate, PMA; phorbol-- 
12,13_dibutyrate, PDBu), but not by 4&phorbol 
[71. 
Although PMA influences phospholipid 
metabolism and agonist-induced elevation of 
[Ca2+]i in neutrophils [8,9], its effects on inositol 
lipid metabolism and [Ca2’]i in platelets have not 
been examined. We show here that PMA and 
PDBu, but not 4&phorbol, impair the transduc- 
tion processes, namely phosphoinositide 
metabolism and elevation of [Ca2+]i, that follow 
the combination of thrombin, vasopressin and 
PAF with their receptors on the platelet plasma 
membrane. 
2. EXPERIMENTAL 
Phospholipid studies were carried out on 
platelets isolated from fresh human blood essen- 
tially as previously described [lo]. Briefly, platelets 
suspended in a Ca2+-free, phosphate-free, Hepes 
buffer (pH 7.4) were incubated (37°C 90 min) 
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with carrier-free [32P]orthophosphate (30 ,&i/ml). 
Platelets were then pelleted, resuspended in 1.5 
times the labelling volume of fresh buffer and ali- 
quots (0.4 ml, 0.5-l mg protein) were dispensed 
into plastic tubes at 37°C. PMA, PDBu, 4,& 
phorbol or dimethyl sulphoxide (DMSO) (as con- 
trol) were added for 2 min and reactions were in- 
itiated by the addition of agonists: PAF (10 nM); 
vasopressin (100 nM); thrombin (0.1 U/ml). After 
30 s reactions were terminated [lo] and lipids were 
extracted, dried at 40°C under N2, separated by 
2-dimensional thin-layer chromatography [1 l] and 
visualized by exposure to iodine vapour. The spots 
corresponding to PtdOH were scraped into vials 
and counted for radioactivity in a liquid scintilla- 
tion counter. Note that under the conditions of 
these experiments changes in [32P]PtdOH reflect 
changes in PtdOH concentration [12]. 
Platelet cytosolic free Ca2+ ([Ca2+]i) was 
monitored essentially as described previously [ 131 
using the fluorescent quinoline dye, quin2 [14]. 
Quin2-labelled platelets were separated from 
plasma containing extraneous dye by gel filtration 
on columns of Sepharose 2B equilibrated with a 
modified Hepes-buffered Tyrodes solution. The 
quin2 content of platelets was around 1 mmol/l 
cell H20. Gel-filtered platelets were stored at 37°C 
in stoppered plastic tubes, and the external free 
Ca2+ concentration was adjusted to 1 mM by addi- 
tion of CaCl2 immediately before use. Platelets 
(2 ml, -5 x 10’ cells/ml) were placed in 1 cm 
square quartz cuvettes at 37°C and fluorescence 
was monitored in a Perkin-Elmer LS3 
Fluorescence Spectrometer at 37°C with standard 
monochromator settings of 339-nm excitation and 
492-nm emission. 
2.1 . Materials 
Thrombin, vasopressin, PMA, PDBu and 4,& 
phorbol were obtained from Sigma, London. PAF 
was purchased from Bachem, Bubbendorf, 
Switzerland and quinZAM from Lancaster Syn- 
thesis, Morecambe, England. PMA, PDBu and 
4&phorbol were dissolved in DMSO. 
3. RESULTS 
4&Phorbol or PMA (g 1.6 /cM) did not 
significantly alter the levels of [32P]PtdOH in 
resting platelets. Thrombin (0.1 U/ml), vaso- 
pressin (100 nM) and PAF (10 nM) stimulated 
[32P]PtdOH formation respectively 5.1 + 0.9-fold, 
2.5 f 0.5-fold and 3.2 + 0.7-fold (mean + SE) over 
basal levels. Prior exposure of platelets to PMA 
(16 nM-I .6 PM) but not to 4&phorbol(< 1.6 PM) 
resulted in a concentration-dependent i hibition of 
[32P]PtdOH formation induced by all 3 agonists 
(fig.1). PDBu (200 nM) exerted effects similar to 
PMA (fig.2). 
Using quinZlabelled platelets, suspended in 
medium of [Ca2’], = 1 mM, PAF (l-100 nM), 
Fig.1. Effects of PMA and 4&phorbol on PAF-, 
vasopressin- and thrombin-induced [32P]PtdOH 
formation in human platelets. Platelets pre-labelled with 
32P04 were incubated (2 min, 37°C) with qB-phorbol 
(1.6 FM) or PMA at the concentrations indicated prior 
to addition of PAF (10 nM), vasopressin (VP, 100 nM) 
or thrombin (0.1 U/ml) for 30 s. Reactions were 
quenched and phospholipids extracted, separated and 
the levels of [32P]PtdOH were monitored. Preliminary 
studies indicated that the effects of 4&phorbol (1.6 FM) 
were not significantly different from those of its vehicle 
DMSO. To facilitate comparison, results (mean values k 
SE of triplicate determinations) are expressed as a 
percentage of the control (saline) sample, in each 
experiment. Control values (mean f SE = 352 f 
34 cpm/mg protein) ranged from 202-608 cpm/mg 
protein in different experiments. The data shown are 
representative of at least 2 similar experiments 
performed using platelets obtained from different 
donors. 
161 
Volume 180, number 2 FEBS LETTERS January 1985 
[32Pl-Ptd OH: % Of Control 
Fin.2. Effects of PDBu on PAF-, vasopressin- and 
AddltiOns 0 100 200 300 400 500 - 1 1 I thrombin-induced [3ZP]PtdOH formation in human 
’ 1' 2 ’ platelets. Platelets pre-labelled with 32P04 were 
incubated (2 min, 37°C) with 4fl-phorbol (1.6 PM) or 
Saline 
I 
PDBu (200 nM) prior to addition of PAF (10 nM), 
4 i3 -Phoruol Saline vasopressin (VP, 100 nM) or thrombin (0.1 U/ml) for 
POBU 
30 s. Other experimental conditions were as stated in the 
legend to fig. 1. The data shown are representative of at 
least 2 similar experiments obtained using platelets from 
different donors. 
VP 
vasopressin (5-500 nM) and thrombin (0.005-0.5 
U/ml) cause an elevation of [Ca*+]i from a resting 
value of 90 +_ 3 nM (mean f SE, n = 42) to a max- 
imum of 480 + 100 nM, 420 f 80 nM and 5 10 f 
4 d -Phorbol 
180 nM, respectively (mean k SE, n = 6-12). 
Thrombln When pre-incubated with platelets for 2 min at 
PDBu 37”C, PMA and 4&phorbol (< 1.6pM) did not 
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Fig.3. Effects of PMA and +%phorbol on PAF-, vasopressin- and thrombin-induced elevation of platelet [Ca’+]r. 
Plasma-free suspensions of quinZlabelled platelets in a modified Hepes-buffered Tyrodes solution containing 1 mM 
external Ca2+ were incubated (37’C, 2 min) with DMSO (control), 4@-phorbol(l60 nM) or PMA at the concentrations 
indicated. Fluorescence responses (excitation 339 nm, emission 492 nm) of 2 ml samples were monitored following the 
addition of PAF (10 nM), vasopressin (50 nM) or thrombin (0.025 U/ml). The appropriate intracellular free Ca2+ 
calibration scale is shown at the right of the fluorescence records. The data shown are typical of 3 similar experiments 
using platelets from different donors. 
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alter resting [Ca”]i. However, PMA (16 nM-1.6 
yM) but not 4&phorbol (< 1.6 PM) inhibited, in a 
concentration-dependent manner, the elevation of 
[Ca2’]i induced by all 3 agonists (fig.3). PDBu also 
impaired agonist-induced elevation of platelet 
[Ca2+]i (not shown). 
4. DISCUSSION 
The platelet stimulatory effects of PMA and 
related tumour-promoting phorbol esters were first 
recognised 10 years ago [IS]. The mechanism(s) 
underlying such platelet stimulatory effects re- 
mained elusive until the demonstration by 
Nishizuka and colleagues [2,7] that these com- 
pounds mimic the effect of endogenous (or ex- 
ogenous) DAG in activation of protein kinase C. 
PMA- or DAG-induced platelet functional 
responses are not accompanied by elevation of 
platelet [Ca’+]i, thus Rink and colleagues [16] pro- 
posed that platelet activation can occur by pro- 
cesses both dependent and independent of eleva- 
tion of [Ca2+]i. As phosphoinositide hydrolysis 
may be the receptor-operated molecular event that 
leads to DAG formation and elevation of [Ca2+]r, 
it is now believed that agonist-induced platelet ac- 
tivation results, partly at least, from the synergistic 
interaction of DAG (via activation of protein 
kinase C) and increased [Ca2+]i (via activation of 
Ca’+-calmodulin dependent protein kinases) 
[4,16]. 
Such a synergistic interaction between (Ca2+]i 
and DAG apparently operates in many systems in- 
cluding adrenal medullary cells, pancreatic islets 
and neutrophils [ 17- 191. Besides interacting 
synergistically with [Ca2+]i to mediate cellular ac- 
tivation, PMA and related phorbol ester activators 
of protein kinase C may modulate [Ca2+]i and in- 
fluence phosphoinositide metabolism [8,9]. For ex- 
ample, in neutrophils, tumour-promoting phorbol 
esters have been reported to stimulate 
arachidonate incorporation into PtdIns [20], 
directly elevate [Ca’+]i [8], have no effect on 
[Ca’+]i [21], impair agonist-induced elevation of 
[Ca2+]i [9] and promote Ca2+ extrusion [22,23]. 
To investigate the possibility that protein kinase 
C may exert inhibitory effects on the transduction 
processes that link receptor occupancy to cellular 
response, we compared the effects of active (PMA, 
PDBu) and inactive (4,&-phorbol) protein kinase C 
stimulants on phosphoinositide metabolism and 
Ca2+ flux in human platelets. PMA does not alter 
the resting level of [Ca2+]i or [32P]PtdOH, but sup- 
presses the elevation of [Ca’*]i and [32P]PtdOH 
formation induced by thrombin, vasopressin and 
PAF. These effects of PMA are shared by PDBu 
but not by 4,&phorbol, and thus can be attributed 
to protein kinase C activation. Suppression by 
PMA of agonist-induced elevation of [Ca2+]i could 
be attributed to activation of a Ca2+ extrusion pro- 
cess, as occurs in neutrophils [23]. Were such a 
mechanism to operate in platelets one might expect 
to observe a reduction in basal [Ca2+]i. The fact 
that this was not observed may indicate either that 
phorbol esters do not activate Ca2’ extrusion in 
platelets, or that Ca2+ extrusion is not activated 
unless there is a concomitant elevation of [Ca2+]i. 
As phosphoinositide metabolism is implicated in 
Ca2+ mobilisation, there may be a cause and effect 
relationship between suppression of [32P]PtdOH 
formation and attenuation of Ca2+ flux, especially 
if the former were to reflect inhibition of 
phospholipase C. However, inhibition of 
[32P]PtdOH formation could be explained by in- 
hibition of PtdIns4P kinase causing depletion of 
PtdIns4,5Pz [24], by inhibition of DAG kinase or 
by activation of PtdOH-phosphohydrolase. Deple- 
tion of PtdIns4,5P2 is unhkely to explain the 
observed effects, as PMA promotes incorporation 
of 32P into PtdIns4P > PtdIns4,SPz [25], an obser- 
vation we have confirmed (not shown). 
The inhibition of agonist-induced [32P]PtdOH 
formation by PMA and PDBu, reported in this 
study, is at variance with the findings of Lapetina 
[26], who observed no inhibition of thrombin 
(0.5 U/ml)-induced [32P]PtdOH formation fol- 
lowing incubation of platelets with PDBu (200 nM, 
30 s). The reasons for this discrepancy are 
unknown but may be related to the differences in 
incubation conditions or agonist concentration 
utilised in the two studies. 
Although the effects of tumour-promoting 
phorbol esters on platelet phosphoinositide 
metabolism await clarification, the results of this 
study suggest hat protein kinase C may function 
as a bi-directional regulator of platelet function. It 
can act independently, or synergistically with 
[Ca2’]i, to mediate platelet activation, and it can 
suppress the transduction processes that link recep- 
tor occupancy to cellular response. These divergent 
163 
Volume 180, number 2 FEBS LETTERS January 1985 
effects may be attributed to the degree of protein 
kinase C activation or expression. Clearly agonist- 
induced platelet activation, associated with 
phosphoinositide hydrolysis, and elevation of 
[Ca2+]i occur under conditions where expression of 
protein kinase C is sub-maximal. Inhibition of 
receptor-mediated Ca2+ flux and [32P]PtdOH for- 
mation may require a greater degree of protein 
kinase C activation or expression: this may be 
achieved either by prior exposure of platelets to 
tumour-promoting phorbol esters or following 
prolonged exposure of platelets to agonists. The 
latter may be of importance in the termination of 
the transduction processes involved in platelet ac- 
tivation and may be implicated in the onset of 
homologous or heterologous desensitisation of 
platelet responsiveness. Whether such mechanisms 
operate in other cell types remains to be 
determined. 
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